New 'Smart Bomb' drug seeks to target and destroy tough blood cancers
NCT ID NCT06034470
Summary
This early-stage study aims to find a safe and effective dose of a new targeted drug, pivekimab sunirine, when given with a standard chemotherapy regimen (FLAG-Ida). It is for adults newly diagnosed with aggressive, high-risk blood cancers like acute myeloid leukemia (AML). The new drug is designed to act like a 'smart bomb,' attaching specifically to cancer cells to deliver a chemotherapy payload directly to them.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.